🇺🇸 FDA
Pipeline program

TG-1801

TG-1801-102

Phase 1 mab terminated

Quick answer

TG-1801 for CLL is a Phase 1 program (mab) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
TG THERAPEUTICS, INC.
Indication
CLL
Phase
Phase 1
Modality
mab
Status
terminated

Clinical trials